According to the Russian health minister Mikhail Murashko, the program will first vaccinate doctors and teachers provided their first vaccine receives regulatory approval this month.
Today Pfizer and BioNTech have jointly announced they are prepared to begin their Phase II/III global trials for their COVID-19 vaccine partnership. Following on review of Phase I/II trial results, the partnership worked with the FDA to select BNT162b2 as the vaccine candidate in the next phases.
Pfizer and BioNTech biopharmaceutics announced today a $1.95 billion dollar agreement with the U.S. government for 100 million doses of the partnership's BNT162 program vaccine.
The first vaccines for the COVID-19 pandemic may arrive in just shy of two months from today according to the World Health Organization (WHO) and several vaccine manufacturers.